Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. regarding potential breaches of fiduciary duties by certain officers and directors of the company [1]. Group 1: Investigation Details - The investigation focuses on whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to the company [1]. - Shareholders who purchased Unicycive shares prior to March 29, 2024, and still hold them can seek corporate reforms and the return of funds at no cost [2][4]. Group 2: Allegations - A federal securities fraud class action complaint alleges that Unicycive's officers made false statements regarding the company's readiness to meet FDA manufacturing compliance requirements, overstating their regulatory prospects [3]. - The complaint claims that the public statements made by the defendants were materially false and misleading at all relevant times [3].

Core Insights - MetaVia Inc. is set to present its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026 [1] - The company is developing DA-1726, an oxyntomodulin analogue, for obesity treatment, and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is publicly traded on Nasdaq under the ticker MTVA [1] Product Pipeline - DA-1726 is a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [1] - In a Phase 1 trial, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction [1] - Vanoglipel is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation and glucose metabolism in pre-clinical studies [1] - In a Phase 2a clinical study, vanoglipel exhibited direct hepatic action alongside glucose-lowering effects [1]

Core Insights - The company expects to complete conditional Marketing Authorization Application submissions to the U.K. and European regulatory agencies by the end of Q1 2026 [1] - Additional biomarker data from the Human Metastatic Osteosarcoma Program is set to be released in Q1 2026, which aims to support the use of biomarkers as surrogate endpoints for clinical efficacy [2] - The company acquired listeria-based assets from Ayala Pharmaceuticals in April 2025, and Ayala has since liquidated its shares in the company [3] Technical Analysis - The stock is currently trading 8.0% below its 20-day simple moving average and 15.0% below its 100-day simple moving average, indicating short-term weakness [4] - Over the past 12 months, shares have decreased by 38.07%, reflecting ongoing challenges for the company [4] - The RSI is at a neutral level, and MACD is also neutral, suggesting mixed momentum for the stock [5] Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $18.25, with recent analyst moves maintaining a target of $20 [6] - OS Therapies shares were up 2.46% at $1.25 during premarket trading [6] - Key resistance is identified at $1.50 and key support at $1.12 [6]

Disc Medicine (NasdaqGM:IRON) Update / briefing February 17, 2026 08:00 AM ET Company ParticipantsDerek Archila - Managing DirectorDouglas Tsao - Managing DirectorJohn Quisel - CEORami Katkhuda - Managing DirectorSean Laaman - Executive DirectorStephen Willey - Managing DirectorWill Savage - Chief Medical OfficerConference Call ParticipantsBulchum Patel - AnalystEvan Seigerman - AnalystKristen Kluska - Equity Research AnalystRoger Song - Senior Equity Research AnalystNone - AnalystNone - AnalystOperatorGood ...

Core Insights - Sana Biotechnology, Inc. has appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial and operational expertise [1][2] - The company anticipates generating initial clinical data for its therapies SC451 and SG293 within the next 12-18 months, which are aimed at treating type 1 diabetes and B-cell related diseases, respectively [2] - The leadership of Mr. Piper is expected to be critical in advancing the company's portfolio and optimizing long-term value creation [2][3] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, with a vision to repair and control genes and replace missing or damaged cells [4] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [4]

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET [Accessibility Statement] Skip NavigationSAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET to discuss fourth quarter and full-year 2025 financial results ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial si. ...

Core Insights - Cardio Diagnostics Holdings, Inc. will host an investor conference call on February 18, 2026, at 3 p.m. Central Time to discuss its precision molecular approach to cardiovascular disease prevention and early detection [1] - The call will cover updates on commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent clinical data, reimbursement progress, and strategic growth initiatives [1] Company Overview - Cardio Diagnostics is a precision cardiovascular medicine company utilizing epigenetics, genetics, and artificial intelligence to enhance the prevention and detection of cardiovascular disease [1] - The company aims to make cardiovascular disease management more accessible, personalized, and precise through its proprietary AI-driven Integrated Genetic-Epigenetic Engine [1] Financial and Operational Updates - The Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests [1] - The company is actively pursuing strategic partnerships, including a recent collaboration with Aimil Ltd. and Dr. Lal PathLabs to launch the PrecisionCHD™ test in India [1]

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it has selected a leading contract research organization (CRO) for SOTERIA, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx’s lead candidate, PLX-200, across four different LSDs. “Our selection of ...

Fourth Quarter and Full Year 2025 Financial and Operating Results February 17, 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements and Disclosures This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the "Company"), including but not limited to, statements about our U.S., Germany, ...